The first U.S. participants has been dosed in the global portion of a clinical trial program testing if Skyhawk Therapeutics’ experimental therapy SKY-0515 can slow the progression of Huntington’s disease. The global portion (NCT07378644) of the Phase 2/3 trial program, called FALCON-HD, is enrolling up to 400…
Discussion
Years ago, my wife, Jill, who is gene-positive for Huntington’s disease, was visiting a relative in a nursing home when she noticed a troubling interaction between a patient and a staff member in the hallway. She could have kept walking. Instead, she stepped in to calm things down and…
Discussion
There is something unsettling about living with a disease that people seem to take more seriously when you are struggling than when you are doing well. I have lived with Huntington’s disease (HD) for more than a decade. During that time, I have learned how to manage my…
Discussion
The U.S. Food and Drug Administration (FDA) has agreed to review uniQure’s application seeking accelerated approval of AMT-130, a gene therapy candidate for Huntington’s disease that is now called ifezuntirgene inilparvovec. “The FDA’s acceptance of our [application] for review marks an important milestone for the Huntington’s disease community,”…
Becoming educated and informed about Huntington’s disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your Huntington’s disease journey.
There is no cure for Huntington’s disease yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
